相似文献
1
Corrigendum to 'Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States': [ESMO Open Volume 6, Issue 5, October 2021, 100252].《心血管不良事件与美国真实世界临床数据中免疫检查点抑制剂的使用相关》勘误：[《ESMO 开放》第 6 卷，第 5 期，2021 年 10 月，100252]
ESMO Open. 2021 Dec;6(6):100286. doi: 10.1016/j.esmoop.2021.100286. Epub 2021 Oct 19.
2
Corrigendum to 'Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review': [ESMO Open Volume 6, Issue 5, October 2021, 100276].《检查点抑制剂、生育力、妊娠和性生活：一项系统综述》勘误：[《ESMO 开放》第 6 卷，第 5 期，2021 年 10 月，100276]
ESMO Open. 2021 Dec;6(6):100291. doi: 10.1016/j.esmoop.2021.100291. Epub 2021 Oct 13.
3
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.在美国的真实世界临床数据中，心血管不良事件与免疫检查点抑制剂的使用相关。
ESMO Open. 2021 Oct;6(5):100252. doi: 10.1016/j.esmoop.2021.100252. Epub 2021 Aug 27.
4
Corrigendum to 'Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study': [ESMO Open Volume 5, Issue 6, 2020, e000985].《ERBB2外显子16跳跃的临床意义：一项真实世界回顾性观察队列研究的分析》勘误：[《ESMO开放》第5卷，第6期，2020年，e000985]
ESMO Open. 2021 Feb;6(1):100052. doi: 10.1016/j.esmoop.2021.100052. Epub 2021 Jan 23.
5
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].《晚期非小细胞肺癌一线纳武利尤单抗联合伊匹木单抗与2周期化疗对比单纯化疗（4周期）：CheckMate 9LA 2年更新》勘误：[《ESMO Open》第6卷，第5期，2021年10月，100273]
ESMO Open. 2021 Dec;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 2.
6
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration.美国食品和药物管理局批准的免疫检查点抑制剂的临床获益。
BMC Cancer. 2020 Aug 31;20(1):823. doi: 10.1186/s12885-020-07313-2.
7
Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.免疫检查点抑制剂使用后的结肠炎：向 FDA 不良事件报告系统提交的自发报告的真实世界分析。
Int Immunopharmacol. 2020 Jul;84:106601. doi: 10.1016/j.intimp.2020.106601. Epub 2020 May 16.
8
Corrigendum to 'Remembering Professor José Baselga': [ESMO Open Volume 6, Issue 3, June 2021, 100121].《缅怀何塞·巴塞尔加教授》勘误：[《ESMO 开放》第 6 卷，第 3 期，2021 年 6 月，100121]
ESMO Open. 2021 Aug;6(4):100221. doi: 10.1016/j.esmoop.2021.100221. Epub 2021 Jul 7.
9
Corrigendum to 'How I treat medullary thyroid cancer': [ESMO Open Volume 6, Issue 3, June 2021, 100183].《我如何治疗甲状腺髓样癌》勘误：[《ESMO 开放杂志》第 6 卷，第 3 期，2021 年 6 月，100183]
ESMO Open. 2022 Jun;7(3):100516. doi: 10.1016/j.esmoop.2022.100516. Epub 2022 Jun 7.
10
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.免疫检查点抑制剂的内分泌毒性：一项利用美国食品和药物管理局不良事件报告系统的真实世界研究。
J Immunother Cancer. 2019 Nov 6;7(1):286. doi: 10.1186/s40425-019-0754-2.
Zotero 插件